title: Human ribonuclease with a pendant poly(ethylene glycol) inhibits tumor growth in mice.
abstract: Human pancreatic ribonuclease (RNase 1) is a small secretory protein that catalyzes the cleavage of RNA. This highly cationic enzyme can enter human cells spontaneously but is removed rapidly from circulation by glomerular filtration. Here, this shortcoming is addressed by attaching a poly(ethylene glycol) (PEG) moiety to RNase 1. The pendant has no effect on ribonucleolytic activity but does increase persistence in circulation. The RNase 1-PEG conjugates inhibit the growth of tumors in a xenograft mouse model of human lung cancer. Both retention in circulation and tumor growth inhibition correlate with the size of the pendant PEG. A weekly dose of the 60-kDa conjugate at 1 µmol/kg inhibited nearly all tumor growth without affecting body weight. Its molecular efficacy is ∼5000-fold greater than that of erlotinib, which is a small molecule in clinical use for the treatment of lung cancer. These data demonstrate that the addition of a PEG moiety can enhance the in vivo efficacy of human proteins that act within cells and highlight a simple means of converting an endogenous human enzyme into a cytotoxin with potential clinical utility.
authors.affiliation: Department of Biochemistry, University of Wisconsin-Madison, Madison, WI.
authors.forename: Thomas J
authors.initials: TJ
authors.lastname: Rutkoski
authors.forename: John A
authors.initials: JA
authors.lastname: Kink
authors.forename: Laura E
authors.initials: LE
authors.lastname: Strong
authors.forename: Ronald T
authors.initials: RT
authors.lastname: Raines
references.citation: Oncologist. 2005 Aug;10(7):461-6
references.pmid: 16079312
references.citation: Biochemistry. 2010 Dec 21;49(50):10666-73
references.pmid: 21062061
references.citation: Protein Expr Purif. 2001 Jul;22(2):174-9
references.pmid: 11437592
references.citation: Neoplasma. 2010;57(4):339-48
references.pmid: 20429625
references.citation: Mol Biosyst. 2005 Oct;1(4):294-302
references.pmid: 16880994
references.citation: Nucleic Acids Res. 2003 Feb 1;31(3):1024-32
references.pmid: 12560499
references.citation: Prog Nucleic Acid Res Mol Biol. 2005;80:349-74
references.pmid: 16164979
references.citation: Cancer Biol Ther. 2011 Aug 1;12(3):208-14
references.pmid: 21633186
references.citation: Cancer Genomics Proteomics. 2012 May-Jun;9(3):119-33
references.pmid: 22593247
references.citation: Nat Rev Drug Discov. 2003 Mar;2(3):214-21
references.pmid: 12612647
references.citation: J Control Release. 2004 Feb 10;94(2-3):401-10
references.pmid: 14744490
references.citation: Crit Rev Ther Drug Carrier Syst. 2000;17(2):101-61
references.pmid: 10820646
references.citation: Cancer Res. 1976 Nov;36(11 Pt 1):4074-8
references.pmid: 975050
references.citation: J Biol Chem. 2003 Jun 6;278(23):20934-8
references.pmid: 12649287
references.citation: Anticancer Drugs. 2002 Feb;13(2):149-54
references.pmid: 11901307
references.citation: J Pharm Sci. 2008 Oct;97(10):4167-83
references.pmid: 18200508
references.citation: J Control Release. 2000 Mar 1;65(1-2):271-84
references.pmid: 10699287
references.citation: J Biol Chem. 2001 Nov 16;276(46):43095-102
references.pmid: 11555655
references.citation: J Mol Biol. 2005 Nov 18;354(1):41-54
references.pmid: 16188273
references.citation: Nat Biotechnol. 1999 Mar;17(3):265-70
references.pmid: 10096294
references.citation: Bioconjug Chem. 2004 Nov-Dec;15(6):1304-13
references.pmid: 15546197
references.citation: Nat Rev Drug Discov. 2005 Jun;4(6):477-88
references.pmid: 15931257
references.citation: Arch Biochem Biophys. 1959 May;82(1):70-7
references.pmid: 13650640
references.citation: Neoplasma. 2006;53(5):402-9
references.pmid: 17013534
references.citation: J Pharm Sci. 1994 Apr;83(4):601-6
references.pmid: 8046623
references.citation: Neoplasma. 2006;53(1):79-85
references.pmid: 16416018
references.citation: Curr Pharm Biotechnol. 2008 Jun;9(3):161-8
references.pmid: 18673281
references.citation: FEBS Lett. 2010 Jun 3;584(11):2194-200
references.pmid: 20388512
references.citation: Biochemistry. 2011 Sep 20;50(37):7835-41
references.pmid: 21838247
references.citation: Chem Rev. 1998 May 7;98(3):1045-1066
references.pmid: 11848924
references.citation: Electrophoresis. 1997 Jun;18(7):1109-19
references.pmid: 9237565
references.citation: Protein Eng. 1995 Mar;8(3):261-73
references.pmid: 7479688
references.citation: Curr Pharm Des. 2009;15(23):2665-75
references.pmid: 19689337
references.citation: Biochemistry. 2007 Sep 11;46(36):10308-16
references.pmid: 17705507
references.citation: Cancer Res. 2002 Nov 1;62(21):6132-40
references.pmid: 12414638
references.citation: J Mol Biol. 2007 Apr 27;368(2):434-49
references.pmid: 17350650
references.citation: BioDrugs. 2008;22(1):53-8
references.pmid: 18215091
references.citation: Curr Pharm Biotechnol. 2008 Jun;9(3):185-9
references.pmid: 18673284
references.citation: Biopolymers. 2008;90(3):259-77
references.pmid: 17868092
references.citation: Oncol Res. 2009;18(4):163-71
references.pmid: 20112502
references.citation: Nucleic Acids Res. 1999 Sep 15;27(18):3696-701
references.pmid: 10471739
references.citation: Proc Natl Acad Sci U S A. 1998 Sep 1;95(18):10407-12
references.pmid: 9724716
references.citation: Bioconjug Chem. 2010 Sep 15;21(9):1691-702
references.pmid: 20704261
references.citation: FEBS J. 2009 Mar;276(6):1527-35
references.pmid: 19220462
references.citation: Acc Chem Res. 2009 Aug 18;42(8):1141-51
references.pmid: 19555070
references.citation: Biochem Biophys Res Commun. 2008 Dec 12;377(2):512-514
references.pmid: 18930025
references.citation: Anal Biochem. 2002 Jul 1;306(1):100-7
references.pmid: 12069420